Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00421213 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
A Phase 2 study, sponsored by Alaunos Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00421213: Completed Phase 2 study, sponsored by Alaunos Therapeutics.
NCT00421213 is a Phase 2 study that has completed, run by Alaunos Therapeutics. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00421213, a Phase 2 study, has completed, sponsored by Alaunos Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.
Interventions
- DRUG Darinaparsin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-12 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
What the finished NCT00421213 record still lists
NCT00421213 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which Darinaparsin is the first listed.
NCT00421213 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00421213 about?
NCT00421213 is a clinical study titled "Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers". The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.
What is the current status of trial NCT00421213?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2006-12. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00421213?
The interventions under investigation include: Darinaparsin (DRUG).
Who is sponsoring clinical trial NCT00421213?
This trial is sponsored by Alaunos Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00421213's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia